These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22404517)

  • 1. Review article: bismuth-based therapy for Helicobacter pylori eradication in children.
    Pacifico L; Osborn JF; Anania C; Vaira D; Olivero E; Chiesa C
    Aliment Pharmacol Ther; 2012 May; 35(9):1010-26. PubMed ID: 22404517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pylera for the eradication of Helicobacter pylori infection.
    Saleem A; Qasim A; O'Connor HJ; O'Morain CA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
    Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
    Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
    Demir M; Göktürk S; Oztürk NA; Serin E; Yilmaz U
    Digestion; 2010; 82(1):47-53. PubMed ID: 20410684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
    Shaikh T; Fallone CA
    Can J Gastroenterol Hepatol; 2016; 2016():7321574. PubMed ID: 27446864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.
    Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1255-68. PubMed ID: 22017749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study.
    Tam YH; Yeung CK; Lee KH
    Aliment Pharmacol Ther; 2006 Jul; 24(1):81-6. PubMed ID: 16803605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
    Chung JW; Lee JH; Jung HY; Yun SC; Oh TH; Choi KD; Song HJ; Lee GH; Kim JH
    Helicobacter; 2011 Aug; 16(4):289-94. PubMed ID: 21762268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.
    Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2011 Sep; 34(6):604-17. PubMed ID: 21745241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
    Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
    Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures.
    Goh KL; Manikam J; Qua CS
    Aliment Pharmacol Ther; 2012 May; 35(9):1097-102. PubMed ID: 22404486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
    de Boer SY; v d Meeberg PC; Siem H; de Boer WA
    Neth J Med; 2003 Jun; 61(6):218-22. PubMed ID: 12956102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002].
    Buzás GM; Józan J
    Orv Hetil; 2004 Oct; 145(40):2035-41. PubMed ID: 15559530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of
    Varga M; Drácz L; Kolbenheyer E; Varga F; Patai ÁV; Solymosi N; Patai Á
    Orv Hetil; 2019 Aug; 160(34):1340-1345. PubMed ID: 31423829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
    Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
    Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.